Usefulness of Radium-223 in Patients with Bone Metastases

References

• Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM. Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: an update on literature with case presentation. Int J Mol Imaging 2016;2016:2568031.
   Google Scholar
• Kapoor A, Wu C, Shayegan B, Rybak AP. Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J 2016;10 (11-12):E414–E423.
   Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350 (16):1655–1664.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369 (3):213–223.
   PubMed Web of Science ®Google Scholar
• Lien LME, Tvedt B, Heinrich D. Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. Int J Urol Nurs 2015;9 (1):3–13.
   Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13 (10):983–992.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367 (13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 2013;39 (1):18–26.
   Web of Science ®Google Scholar
• Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12 (20 Pt 2):6250s–6257s.
   PubMed Web of Science ®Google Scholar
• Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res 2013;19 (3):530–537.
   Web of Science ®Google Scholar
• Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17 (9):1306–1316.
   PubMed Web of Science ®Google Scholar
• Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14 (7–8):349–351.
   Google Scholar
• Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 2004;6 (Suppl 10):S3–S12.
   PubMedGoogle Scholar
• Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE. Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer 2017;71:1–6.
   PubMed Web of Science ®Google Scholar
• Xofigo (Radium Ra 223 Dichloride) Injection [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., 2013.
   Google Scholar
• Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies. Am J Clin Oncol 2017;40 (4):342–347.
   Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with α-emitting ##radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11 (12):4451–4459.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8 (7):587–594.
   PubMed Web of Science ®Google Scholar
• Nilsson S. Radium-223 therapy of bone metastases in prostate cancer. Semin Nucl Med 2016;46 (6):544–556.
   Web of Science ®Google Scholar
• Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27 (5):868–874.
   PubMed Web of Science ®Google Scholar
• Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet 2016;387 (10013):70–82.
   PubMed Web of Science ®Google Scholar
• Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15 (12):1397–1406.
   PubMed Web of Science ®Google Scholar
• Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate 2016;76 (10):905–916.
   PubMed Web of Science ®Google Scholar
• Finkelstein SE, Michalski JM, O'Sullivan JM, Parker C, Garcia-Vargas JE, Sartor AO. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. J Clin Oncol 2015;33 (7 Suppl):182.
   Web of Science ®Google Scholar